ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2010
Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis.Annals of medicine · 2023Pooled it
- Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.The Indian journal of medical research · 2020Pooled it
- Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- Trial
- Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes.PloS one · 2011Trial
- Long-Term Risk Trajectories of Diabetes Differ After Direct-Acting Antiviral and Interferon Therapy in Chronic Hepatitis C: A Real-World Cohort Study.Biomedicines · 2026Article
- Article
- Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.Saudi medical journal · 2023Article
- The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.Frontiers in endocrinology · 2021Observational
- Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control.Journal of managed care & specialty pharmacy · 2020Article
- The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.Internal and emergency medicine · 2020Article
- Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication.JHEP reports : innovation in hepatology · 2019Review
- Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis.Experimental and therapeutic medicine · 2019Article
- Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus.Open access Macedonian journal of medical sciences · 2019Article
- Significant HbAFederal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019Article
- Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.The Libyan journal of medicine · 2018Article
- Endocrine disorders associated with hepatitis C virus chronic infection.Reviews in endocrine & metabolic disorders · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsHepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established.
methodsWe performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial to evaluate whether suppression of hepatitis C is associated with improvement in IR. Participants had advanced hepatic fibrosis and carried non-3 HCV genotypes (n = 96). Patients underwent 24 weeks of pegylated interferon and ribavirin therapy and were categorized into HCV clearance groups at week 20 on the basis of HCV RNA levels; null responders had <1 log(10) decline (n = 38), partial responders had >or=1 log(10) decline (n = 37) but detectable HCV RNA, and complete responders had no detectable HCV RNA (n = 21). The primary outcome was change (week 20 minus week 0) in IR by using the homeostasis model assessment (HOMA2-IR).
resultsAdjusting only for baseline HOMA2-IR, mean HOMA2-IR differences were -2.23 (complete responders), -0.90 (partial responders), and +0.18 (null responders) (P = .036). The observed differences in mean HOMA2-IR scores were ordered in a linear fashion across response groups (P = .01). The association between HCV clearance and improvement in HOMA2-IR could not be accounted for by adiponectin or tumor necrosis factor-alpha and was independent of potential confounders including age, gender, ethnicity, body mass index, duration of infection, medications used, and fibrosis.
conclusionsHCV suppression correlates with improvement in IR. These data provide further support for a role of HCV in the development of insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.